Currently, about 10% of women who undergo mammograms have a false-positive result, leading to additional tests, including invasive biopsies. We’re developing a blood test to be administered at the time of breast imaging that could reduce the number of women who are encouraged to get biopsies but do not ultimately have breast cancer.
Our study integrates a protein-based blood test and an AI analysis of mammograms to distinguish benign from malignant breast conditions, reducing unnecessary biopsies and detecting aggressive cancers early and accurately. These blood samples will also aid in correlating breast cancer biomarkers with biopsy results, improving risk assessment, guiding future diagnostic development, and ultimately advancing precision oncology.